GGrantIndex
Sort

82,697 grants matching vaccine development

Designing and optimizing candidate HIV vaccines and boosting protocols

$962,348
David Nemazee · Scripps Research Institute, The · R01 · FY2021 · AI

Designing and optimizing candidate HIV vaccines and boosting protocols

$962,348
David Nemazee · Scripps Research Institute, The · R01 · FY2020 · AI

Translational Research to Prevent and Control Global Infectious Diseases (Translational Global Infectious Diseases Research Center, TGIR).

$962,333
Beth Diane Kirkpatrick · University Of Vermont & St Agric College · P20 · FY2023 · GM

Role of Innate Immune Dysregulation in the Etiology of Dementia

$962,256
Annelise Emily Barron · Stanford University · DP1 · FY2022 · AG

High-throughput immunoproteomics for cancer biomarker discovery

$962,182
Joshua Labaer · Arizona State University-Tempe Campus · U2C · FY2023 · CA

Impact of HIV on the human alveolar environment drivingthe early events of Mycobacterium tuberculosis infection

$962,145
Jordi B Torrelles · Texas Biomedical Research Institute · R01 · FY2025 · AI

Novel Targets for Vaccine Therapy

$962,130
Claudia Palena · Division Of Basic Sciences - Nci · ZIC · FY2014 · CA

Cryopreservation of Anopheles Embryos

$962,110
Peter F. Billingsley · Sanaria, Inc. · R44 · FY2021 · AI

Development

$962,061
Ana M Navarro · University Of California, San Diego · U54 · FY2011 · CA

Characterization of immunogenic and structural properties of HIV-1 envelope

$962,051
Michael W Cho · Iowa State University · P01 · FY2010 · AI

Louisiana Clinical and Translational Science Center

$961,973
John P. Kirwan · Lsu Pennington Biomedical Research Ctr · U54 · FY2021 · GM

P1 - COMBINATION ACTIVATED T-CELL AND VACCINE THERAPY IN MYELOMA

$961,866
Larry W Kwak · University Of Tx Md Anderson Can Ctr · P50 · FY2013 · CA

Enhancing DNA vaccines using modified Bacterial Toxin A1 Subunits as adjuvants

$961,830
Timothy R Fouts · Profectus Biosciences, Inc. · R44 · FY2011 · AI

N-glycan baiting to target the highly effective HIV Env shield

$961,798
Richard Thomas Wyatt · Scripps Research Institute, The · R01 · FY2021 · AI

N-glycan baiting to target the highly effective HIV Env shield

$961,798
Richard Thomas Wyatt · Scripps Research Institute, The · R01 · FY2023 · AI

Vaccine and Treatment Evaluation Units: Protocol Development and Implementation for a Natural History Challenge Study for Influenza

$961,771
Daniel Hoft · Saint Louis University · N01 · FY2019 · AI

4-(Aminomethyl) benzamides as novel anti-Ebola agents

$961,660
Lijun Rong · Chicago Biosolutions, Inc. · R42 · FY2020 · AI

Ebola Virus Disease Animal Model Refinement

$961,399
National Institute Of Allergy And Infectious Diseases · Y01 · FY2017 · AI

Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites

$961,340
Sumana Chakravarty · Sanaria, Inc. · R44 · FY2022 · AI

HIV VACCINE CLINICAL TRIALS UNIT

$961,319
Michael C Keefer · University Of Rochester · U01 · FY2006 · AI

REPTOR: accelerating antibody discovery and improving hits with machine learning

$961,244
Natalie Castellana · Abterra Biosciences, Inc. · R44 · FY2025 · GM

Macaque Core -Core B

$960,730
Vijayakumar Velu · Emory University · U19 · FY2016 · AI

BIOLOGY OF ALIMENTARY EPITHELIA IN HEALTH AND DISEASE

$960,665
Children'S Hospital Boston · P30 · FY2000 · DK

Multiplexed Antigen-Specific Antibody Fc Profiling on a Chip for Point-of-Care Diagnosis of TB in HIV-infected Children

$960,557
Galit Alter · Massachusetts General Hospital · R01 · FY2021 · AI

Systems Biology Approaches to Viral Pathogenesis and Immunity

$960,510
Michael G Katze · Oregon Health & Science University · U54 · FY2011 · AI